947688-87-1

Basic information

• Product Name: 2-(5-broMo-3-Methoxypyridin-2-yl)acetonitrile
• Synonyms: 2-(5-broMo-3-Methoxypyridin-2-yl)acetonitrile
• CAS NO: 947688-87-1
• Molecular Formula: C8H7BrN2O
• Molecular Weight: 227.05798
• Mol File: 947688-87-1.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-(5-broMo-3-Methoxypyridin-2-yl)acetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(5-broMo-3-Methoxypyridin-2-yl)acetonitrile(947688-87-1)
• EPA Substance Registry System: 2-(5-broMo-3-Methoxypyridin-2-yl)acetonitrile(947688-87-1)

Safety Data

• Hazardous Substances Data: 947688-87-1(Hazardous Substances Data)

Usage

Derived from

Pyridine (a heterocyclic aromatic organic compound)

Usage

Building block in the synthesis of pharmaceutical products, agrochemicals, and other organic compounds

Type

Nitrile (contains a carbon triple-bonded to a nitrogen atom)

Versatility

Versatile intermediate in organic synthesis

Substituents

5-Bromo and 3-Methoxy groups

Potential

Exhibits potential biological activity

Safety

Potentially hazardous chemical, should be handled with care and used in accordance with proper safety protocols.

Upstream product

• 286947-03-3 5-bromo-2-chloro-3-methoxy-pyridine 
• 75-05-8 acetonitrile 

Downstream Products

• 952059-92-6 methyl 2-[3-methoxy-5-(7-ethoxy-1,5-naphthyridin-4-yloxy)pyridin-2-yl]acetate 
• 952059-87-9 methyl 2-[3-methoxy-5-(6-methoxy-1,5-naphthyridin-4-yloxy)pyridin-2-yl]acetate 
• 952059-89-1 methyl 2-[3-methoxy-5-(7-methoxy-1,5-naphthyridin-4-yloxy)pyridin-2-yl]acetate 
• 947688-88-2 methyl 2-(5-bromo-3-methoxypyridin-2-yl)acetate 
• 947688-89-3 methyl 2-[3-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)pyridin-2-yl]acetate 
• 947688-90-6 methyl 2-(5-hydroxy-3-methoxypyridin-2-yl)acetate 

Relevant articles and documents

Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases

A new series of quinoline ether inhibitors, which potently and selectively inhibit PDGFR tyrosine kinases, is described in this Letter. Compounds 23 and 33 are selective, low nanomolar inhibitors of PDGFRα and β, display good pharmacokinetics in rat and dog and are active in vivo at low doses when given orally twice daily. Further evaluation of these compounds is warranted.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

NAPHTHYRIDINE DERIVATIVES

The invention concerns naphthyridine derivatives of Formula (Ia) or (Ib) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, G1, G2, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders or disease states associated with angiogenesis and/or vascular permeability.